18889881171
Kalkine 0
countryflagUS

Akoya Biosciences Inc

Healthcare US AKYA

1.265USD
0.005(0.40%)

Last update at 2025-06-13T16:56:00Z

Day Range

1.221.27
LowHigh

52 Week Range

1.886.31
LowHigh

Fundamentals

  • Previous Close 1.26
  • Market Cap111.02M
  • Volume18970
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-39.48600M
  • Revenue TTM93.22M
  • Revenue Per Share TTM1.89
  • Gross Profit TTM 43.39M
  • Diluted EPS TTM-1.16

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -70.51800M -43.07500M -16.66400M -14.55700M
Minority interest - - - -
Net income -70.64100M -42.93500M -16.70600M -14.75100M
Selling general administrative 79.55M 53.09M 23.98M 26.35M
Selling and marketing expenses - - - -
Gross profit 43.39M 34.22M 25.91M 24.66M
Reconciled depreciation 7.15M 4.73M 3.81M 3.06M
Ebit -66.20800M -37.22500M -11.49200M -13.50400M
Ebitda -59.33200M -32.90900M -7.63800M -10.82200M
Depreciation and amortization 6.88M 4.32M 3.85M 2.68M
Non operating income net other 0.14M -0.66200M - -
Operating income -66.20800M -37.22500M -11.49200M -13.50400M
Other operating expenses 141.07M 92.14M 53.94M 55.74M
Interest expense 4.55M 3.12M 2.72M 1.88M
Tax provision 0.12M -0.14000M 0.04M 0.19M
Interest income 0.78M - - -
Net interest income -3.77700M -3.11500M -2.72300M -1.88100M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense 0.12M -0.14000M 0.04M 0.19M
Total revenue 74.86M 54.92M 42.44M 42.24M
Total operating expenses 109.60M 71.44M 37.40M 38.17M
Cost of revenue 31.47M 20.70M 16.54M 17.57M
Total other income expense net -4.31000M -5.85000M -5.17200M -1.05300M
Discontinued operations - - - -
Net income from continuing ops -70.64100M -42.93500M -16.70600M -14.75100M
Net income applicable to common shares -70.64100M -44.37000M -21.76200M -18.30700M
Preferred stock and other adjustments - 1.44M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 180.37M 176.03M 190.91M 77.66M 89.41M
Intangible assets 17.41M 20.05M 21.15M 22.71M 24.14M
Earning assets - - - - -
Other current assets 3.79M 6.76M 9.28M 0.96M 1.96M
Total liab 126.60M 117.45M 69.56M 59.09M 119.57M
Total stockholder equity 53.77M 58.58M 121.35M 18.57M -30.15900M
Deferred long term liab - 0.09M 0.03M 0.27M -
Other current liab 13.43M 16.52M -0.27200M 7.01M 8.58M
Common stock 0.00200M 0.00200M 0.00200M 0.00200M 0.00100M
Capital stock 0.00200M 0.00200M 0.00200M 0.00200M 1.25M
Retained earnings -230.07100M -166.74800M -96.10700M -52.28000M -31.41300M
Other liab - 8.24M 9.40M 8.65M 9.40M
Good will 18.26M 18.26M 18.26M 18.26M 18.26M
Other assets 0.00000M 3.08M 3.19M 2.46M 1.16M
Cash 83.12M 74.23M 113.08M 17.01M 11.64M
Cash and equivalents - - - - -
Total current liabilities 35.34M 37.05M 27.68M 17.16M 21.16M
Current deferred revenue 6.69M 6.28M 4.48M 3.84M 4.38M
Net debt 2.58M 1.55M -80.60800M 17.99M 13.12M
Short term debt 3.45M 3.63M 0.27M 1.23M 0.08M
Short long term debt - - - 1.03M -
Short long term debt total 85.71M 75.78M 32.47M 34.99M 24.75M
Other stockholder equity 283.84M 225.33M 217.46M 70.85M 0.87M
Property plant equipment - 10.17M 7.49M 5.53M 4.98M
Total current assets 121.79M 112.20M 140.81M 28.70M 40.87M
Long term investments - - - - -
Net tangible assets - 20.27M 81.94M -93.25500M -73.81100M
Short term investments 0.00000M 6.99M - 0.00000M 10.02M
Net receivables 16.99M 9.73M 9.44M 6.47M 13.17M
Long term debt 75.25M 63.28M 32.47M 33.49M 24.47M
Inventory 17.88M 14.49M 9.01M 4.26M 4.09M
Accounts payable 11.78M 27.15M 23.20M 5.07M 8.12M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - -0.00600M -190.90700M -2.26400M -0.86600M
Additional paid in capital - - - - -
Common stock total equity - 0.00200M 0.00200M 0.00100M 0.00100M
Preferred stock total equity - - - - -
Retained earnings total equity - -166.74800M -96.10700M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.55M 3.08M 3.19M 2.46M 1.16M
Deferred long term asset charges - - - - -
Non current assets total 58.58M 63.83M 50.09M 48.96M 48.54M
Capital lease obligations 10.45M 12.51M 0.47M 0.47M 0.28M
Long term debt total - 63.28M 32.47M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -6.77400M -5.09400M 10.02M -10.02300M
Change to liabilities 4.45M 10.87M -3.47300M 3.18M
Total cashflows from investing activities -14.07900M -5.09400M 6.73M -12.89200M
Net borrowings 31.01M -0.32200M 9.79M 4.96M
Total cash from financing activities 28.73M 137.03M 5.49M 28.56M
Change to operating activities 4.05M -2.28200M -0.14600M 2.82M
Net income -70.64100M -42.93500M -16.70600M -14.75100M
Change in cash -38.84900M 95.87M 5.37M 1.89M
Begin period cash flow 113.38M 17.51M 12.14M 10.24M
End period cash flow 74.53M 113.38M 17.51M 12.14M
Total cash from operating activities -53.49600M -36.06800M -6.84300M -13.77600M
Issuance of capital stock 0.00000M 138.55M 0.00000M 24.82M
Depreciation 7.15M 4.79M 3.81M 3.06M
Other cashflows from investing activities 0.06M - - -
Dividends paid - -1.43500M - -
Change to inventory -5.37400M -4.62800M -0.68400M -4.00700M
Change to account receivables -0.28500M -2.97400M 6.70M -3.37300M
Sale purchase of stock 0.45M 1.44M - -
Other cashflows from financing activities 29.35M -1.19600M 30.68M 53.60M
Change to netincome 7.45M 6.21M 3.65M -0.70300M
Capital expenditures 7.36M 5.09M 3.29M 2.87M
Change receivables -0.28500M -2.97400M - -
Cash flows other operating 3.38M -7.82700M - -
Exchange rate changes - - - -
Cash and cash equivalents changes -38.84900M 95.87M - -
Change in working capital 2.16M -4.56100M 2.39M -1.37700M
Stock based compensation 7.43M 4.04M 0.48M 0.15M
Other non cash items 0.37M 2.75M 3.17M -1.01200M
Free cash flow -60.85600M -41.16200M -10.13800M -16.64500M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AKYA
Akoya Biosciences Inc		 0.005 0.40% 1.26 - - 1.19 7.71 1.77 -6.8309
ISRG
Intuitive Surgical Inc		 3.60 0.70% 516.61 73.05 61.73 19.15 10.25 18.41 59.92
ESLOY
Essilor International SA		 -2.85 1.99% 140.21 35.39 24.81 3.63 2.20 4.00 16.25
ESLOF
EssilorLuxottica Société anonyme		 3.50 1.23% 287.75 35.71 25.13 3.62 2.23 4.00 16.25
BDX
Becton Dickinson and Company		 0.78 0.44% 175.24 37.72 15.92 3.25 2.49 4.08 17.10

Reports Covered

Stock Research & News

View All

Profile

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Akoya Biosciences Inc

100 Campus Drive, Marlborough, MA, United States, 01752

Key Executives

Name Title Year Born
Mr. Paul Grass Sr. VP of Sales NA
Mr. Brian McKelligon Pres, CEO & Director 1969
Dr. Garry P. Nolan Ph.D. Co-Founder, Independent Director & Head of the Scientific Advisory Board 1962
Mr. Joseph S. Driscoll Chief Financial Officer 1965
Dr. Frederic G. Pla Ph.D. Chief Operating Officer 1959
Dr. Nikolay Samusik Ph.D. Co-Founder NA
Dr. Yury Goltsev Ph.D. Co-Founder NA
Mr. Clifford C. Hoyt VP of Translational & Scientific Affairs NA
Priyam Shah Sr. Director of Bus. Devel. & Investor Relations Strategy NA
Ms. Marilee Moy M.B.A. Chief People Officer 1959

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.